The study evaluated the efficacy and safety of dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, in adults with moderate-to-severe atopic dermatitis. Four randomized, double-blind, placebo-controlled trials were conducted, including two 4-week monotherapy trials, one 12-week monotherapy trial, and one 4-week combination therapy trial. Dupilumab demonstrated rapid and dose-dependent improvements in clinical indexes, biomarker levels, and the transcriptome. In the 12-week monotherapy trial, 85% of patients in the dupilumab group achieved a 50% reduction in the Eczema Area and Severity Index (EASI-50) score, compared to 35% in the placebo group. Pruritus scores also decreased significantly in the dupilumab group. In the combination therapy trial, all patients in the dupilumab group met the EASI-50 criterion, despite using less topical glucocorticoids than those in the placebo group. Adverse events were balanced between the groups, with nasopharyngitis and headache being the most common. The study concluded that dupilumab significantly improved atopic dermatitis symptoms and reduced biomarker levels, suggesting its potential as a treatment for moderate-to-severe atopic dermatitis.The study evaluated the efficacy and safety of dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, in adults with moderate-to-severe atopic dermatitis. Four randomized, double-blind, placebo-controlled trials were conducted, including two 4-week monotherapy trials, one 12-week monotherapy trial, and one 4-week combination therapy trial. Dupilumab demonstrated rapid and dose-dependent improvements in clinical indexes, biomarker levels, and the transcriptome. In the 12-week monotherapy trial, 85% of patients in the dupilumab group achieved a 50% reduction in the Eczema Area and Severity Index (EASI-50) score, compared to 35% in the placebo group. Pruritus scores also decreased significantly in the dupilumab group. In the combination therapy trial, all patients in the dupilumab group met the EASI-50 criterion, despite using less topical glucocorticoids than those in the placebo group. Adverse events were balanced between the groups, with nasopharyngitis and headache being the most common. The study concluded that dupilumab significantly improved atopic dermatitis symptoms and reduced biomarker levels, suggesting its potential as a treatment for moderate-to-severe atopic dermatitis.